The Takeovers Panel has received an application from Atlas Arteria Limited relating to the off-market takeover bid from Diamond Infraco 1 Pty Ltd, a subsidiary of IFM Global Infrastructure Fund. Atlas Arteria is seeking interim and final orders to restrain the bidder from dispatching its statement in the current form, raising questions about the mechanics and legality of the proposed offer structure.
The bid itself is straightforward in headline terms: Diamond Infraco is offering $4.75 per stapled security with an increase to $5.10 per security if the bidder’s relevant interest reaches 45 percent or more prior to close. The bidder currently holds 34.48 percent of Atlas Arteria, giving it significant but not absolute control. The bidder has stated the $5.10 price is best and final and has established an institutional acceptance facility to facilitate shareholder participation.
What makes this application material is Atlas Arteria’s challenge to the very foundation of this two-tiered structure. The company argues the pricing mechanism is inherently flawed and cannot deliver the $5.10 consideration with certainty. Specifically, Atlas Arteria contends the bidder’s statement fails to adequately explain how the two-tier structure complies with section 650D of the Corporations Act, which governs extensions and variations of takeover offers. The concern centers on whether the disclosure sufficiently warns shareholders of the risk that the offer may close at the lower $4.75 price if the bidder falls short of the 45 percent threshold.
There is also a procedural objection regarding the institutional acceptance facility. Atlas Arteria submits that the operation of this facility, combined with disclosure deficiencies, jeopardises the operation of an efficient, competitive and informed market. This challenge goes to the heart of Chapter 6 principles, which govern takeover regulation in Australia and aim to ensure fair treatment of target shareholders and market integrity.
For investors holding Atlas Arteria securities, this application introduces material uncertainty. If the Panel agrees with Atlas Arteria’s arguments, the bidder may be forced to restructure its offer, potentially removing the conditional pricing mechanism entirely and simplifying terms to a single price. Conversely, if the Panel rejects the application or the bidder successfully defends its structure, the offer can proceed as announced. Either outcome carries investment implications, particularly for shareholders evaluating the certainty of proceeds and the relative attractiveness of the conditional pricing mechanics.
The timing is significant. The bidder released its statement on 27 April, and this application comes quickly, suggesting Atlas Arteria views the disclosure and structural issues as sufficiently serious to warrant immediate Panel intervention. The next key development will be whether the Panel appoints a sitting panel and agrees to conduct proceedings. There is no guarantee that it will proceed, and the Panel has made no comment on the merits of the application at this stage. Investors should monitor Panel updates, any amendments the bidder may propose to its statement, and whether ASIC relief is sought to address the structural concerns raised. This announcement is price sensitive and flagged as material by the ASX.
View the full ASX announcement (PDF)
About Atlas Arteria Limited (ASX: ALX)
Atlas Arteria Limited is a global owner, operator, and developer of toll roads with a portfolio spanning France, Germany, and the United States. The company holds significant interests in major toll road networks including approximately 31% of the APRR motorway network in eastern France, the Warnow Tunnel in Germany, the Chicago Skyway in the United States, and full ownership of the Dulles Greenway in Virginia. The company is based in Melbourne, Australia and operates toll road businesses that generate revenue from motorway usage across multiple countries.
If you would like to discuss this announcement or how it might affect your portfolio, request a callback or call us on 1300 889 603.
